Skip to main content
    Z

    Zimmer Biomet Holdings Inc (ZBH)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $101.44
    -1.78 (-1.72%)

    Market Cap: $19.53B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zimmer Biomet Holdings Inc (ZBH) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Zimmer Biomet Holdings reported revenue of $8.23B for the fiscal year ended Dec 31, 2025, up 7.2% from the year before. That year, net income was $705.10M with a net margin of 8.6%, operating cash flow was $1.70B and free cash flow was $1.47B. The quarter ended Sep 30, 2026 had revenue of $2.06B and net income of $191.60M.

    Revenue and Margins

    The operating margin was 13.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $7.62B, a compound annual rate of 0.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$8.23B+7.2%69.7%13.3%8.6%
    Dec 2024$7.68B+3.8%71.5%16.7%11.8%
    Dec 2023$7.39B+6.5%71.8%17.3%13.8%
    Dec 2022$6.94B+1.6%70.9%10.0%3.3%
    Dec 2021$6.83B+11.4%71.3%12.6%5.9%
    Dec 2020$6.13B-23.2%70.2%1.4%-2.2%
    Dec 2019$7.98B+0.6%71.8%14.3%14.2%
    Dec 2018$7.93B+1.7%71.4%0.4%-4.8%
    Dec 2017$7.80B+2.5%72.7%10.2%23.2%
    Dec 2016$7.62BN/A68.7%10.8%4.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 22.0% from the year before. In the quarter ended Sep 2026, net income fell 17.0% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$8.23B$7.68B$7.39B$6.94B$6.83B$6.13B$7.98B$7.93B$7.80B$7.62B
    Cost of revenue$2.49B$2.19B$2.08B$2.02B$1.96B$1.82B$2.25B$2.27B$2.13B$2.38B
    Gross profit$5.74B$5.49B$5.31B$4.92B$4.87B$4.30B$5.73B$5.66B$5.67B$5.23B
    Research and development$458.50M$437.40M$458.70M$406.00M$435.80M$322.80M$449.30M$391.70M$369.90M$365.60M
    Operating income$1.10B$1.29B$1.28B$696.30M$860.30M$83.10M$1.14B$33.80M$799.30M$821.10M
    Net income$705.10M$903.80M$1.02B$231.40M$401.60M-$137.40M$1.13B-$379.30M$1.81B$304.60M
    EBITDA$2.22B$2.25B$2.22B$1.49B$1.81B$1.01B$2.14B$1.06B$1.85B$1.79B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.06B$2.18B$2.09B$2.24B$2.00B$2.08B$1.91B$2.02B$1.82B$1.94B$1.89B$1.94B
    Gross profit$1.47B$1.54B$1.51B$1.45B$1.44B$1.49B$1.36B$1.44B$1.29B$1.39B$1.38B$1.40B
    Operating income$307.60M$326.10M$373.20M$154.50M$351.30M$300.00M$292.30M$389.00M$279.50M$351.30M$265.90M$354.20M
    Net income$191.60M$198.30M$238.10M$139.40M$230.90M$152.80M$182.00M$239.50M$249.10M$242.80M$172.40M$418.90M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $7.52B exceeded cash and equivalents by $6.93B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$23.09B$21.37B$21.50B$21.07B$23.46B$24.42B$24.64B$24.13B$26.01B$26.68B
    Current assets$5.12B$4.67B$4.61B$4.43B$4.88B$5.08B$4.72B$4.43B$4.56B$4.66B
    Cash and equivalents$591.90M$525.50M$415.80M$375.70M$378.10M$802.10M$617.90M$542.80M$524.40M$634.10M
    Total liabilities$10.39B$8.89B$9.01B$9.04B$10.79B$12.22B$12.25B$12.85B$14.28B$17.01B
    Short-term debt$587.10M$863.00M$900.00M$544.30M$1.61B$500.00M$1.50B$525.00M$1.23B$575.60M
    Long-term debt$6.93B$5.34B$4.87B$5.15B$5.46B$7.63B$6.72B$8.41B$8.92B$10.67B
    Shareholder equity$12.70B$12.47B$12.48B$12.02B$12.66B$12.19B$12.39B$11.27B$11.74B$9.67B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$23.54B$22.80B$22.72B$23.09B$23.49B$22.87B$22.18B$21.37B$21.72B$21.52B$21.45B$21.50B
    Total liabilities$10.81B$10.17B$10.04B$10.39B$10.72B$10.33B$9.78B$8.89B$9.34B$8.77B$8.85B$9.01B
    Cash and equivalents$399.90M$410.00M$424.20M$591.90M$1.29B$556.90M$1.38B$525.50M$569.00M$420.10M$393.00M$415.80M
    Shareholder equity$12.72B$12.62B$12.67B$12.70B$12.76B$12.53B$12.40B$12.47B$12.37B$12.74B$12.60B$12.48B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 86.5% of operating cash flow. Dividends and share repurchases together came to 46.1% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$1.70B$1.50B$1.58B$1.36B$1.40B$1.08B$1.59B$1.75B$1.58B$1.63B
    Capital expenditures$224.50M$203.80M$291.10M$187.90M$143.60M$111.90M$207.10M$162.70M$156.00M$184.70M
    Free cash flow$1.47B$1.30B$1.29B$1.17B$1.26B$963.70M$1.38B$1.58B$1.43B$1.45B
    Dividends paid$190.30M$196.00M$200.90M$201.20M$345.10M$198.50M$196.70M$195.20M$193.60M$188.40M
    Share repurchases$487.00M$868.00M$692.20M$126.40M$0$0N/AN/AN/A$415.50M
    Investing cash flow-$1.98B-$888.10M-$778.90M-$522.00M-$443.30M-$564.30M-$729.30M-$416.60M-$510.80M-$1.69B
    Financing cash flow$326.00M-$484.50M-$763.50M-$775.70M-$1.31B-$420.20M-$779.90M-$1.30B-$1.21B-$743.20M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$560.00M$447.80M$359.40M$517.40M$418.70M$378.20M$382.80M$506.30M$395.70M$369.40M$228.00M$588.40M
    Capital expenditures$75.80M$54.20M$36.30M$74.80M$55.00M$50.10M$44.60M$51.50M$44.50M$52.70M$55.10M$62.80M
    Free cash flow$484.20M$393.60M$323.10M$442.60M$363.70M$328.10M$338.20M$454.80M$351.20M$316.70M$172.90M$525.60M
    Last 12 quarters

    Frequently Asked Questions About ZBH

    What is Zimmer Biomet Holdings' annual revenue?

    Zimmer Biomet Holdings reported revenue of $8.23B for the fiscal year ended Dec 31, 2025.

    How fast is Zimmer Biomet Holdings' revenue growing?

    Revenue was up 7.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.9%.

    Is Zimmer Biomet Holdings profitable?

    Yes. Zimmer Biomet Holdings reported net income of $705.10M for the fiscal year ended Dec 31, 2025, with a net margin of 8.6%.

    How much free cash flow does ZBH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $1.70B minus capital expenditures of $224.50M produced free cash flow of $1.47B.

    How much debt does Zimmer Biomet Holdings have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $6.93B, short-term debt of $587.10M and cash and equivalents of $591.90M.